Long-term clinical evidence of comparable efficacy and toxicity of nivolumab and pembrolizumab in advanced melanoma treatment.
Cybulska-Stopa B, Piejko K, Ostaszewski K, Dziura R, Galus Ł, Ziółkowska B, Kempa-Kamińska N, Ziętek M, Bal W, Kamycka A, Dudzisz-Śledź M, Kubiatowski T, Kamińska-Winciorek G, Suwiński R, Mackiewicz J, Czarnecka AM, Rutkowski P.
Cybulska-Stopa B, et al. Among authors: ostaszewski k.
Melanoma Res. 2023 Jun 1;33(3):208-217. doi: 10.1097/CMR.0000000000000885. Epub 2023 Apr 3.
Melanoma Res. 2023.
PMID: 37015054